tiprankstipranks
Cryo-Cell International Inc (CCEL)
NYSE MKT:CCEL

Cryo-Cell International (CCEL) Stock Price & Analysis

34 Followers

CCEL Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.67 - $8.15
Previous Close$7.72
Volume3.52K
Average Volume (3M)11.13K
Market Cap
$62.57M
Enterprise Value$73.36M
Total Cash (Recent Filing)$980.25K
Total Debt (Recent Filing)$11.77M
Price to Earnings (P/E)-6.6
Beta0.18
Jul 12, 2024
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding8,104,477
10 Day Avg. Volume10,497
30 Day Avg. Volume11,127
Standard Deviation0.19
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-4.48
Price to Sales (P/S)8.10
Price to Cash Flow (P/CF)4.70
P/FCF Ratio8.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.12
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda-7.53
Forecast
Price Target Upside15.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say
Business StrategyCryo-Cell's exploration of strategic alternatives to spin off its drug trial and clinic businesses could unlock additional shareholder value.
EarningsAnalyst's recommendation is reinforced with the company's recent EBITDA beat, prompting an increase in the price target.
Operational StrengthThe company's core business in processing and storing stem cells is recognized for its high margins and potential for recurring revenue.
Bears Say
Earnings ConcernsInvestor confidence might be shaken as the company's EBITDA missed estimates because of non-cash impairment charges, negatively impacting the bottom line.
Forecast AdjustmentsThe company's future growth prospects could be questioned as analysts have lowered revenue and EBITDA forecasts, awaiting results from the Phase 2 Autism trial.
Regulatory RisksThe stock may face volatility as the company's Phase 3 clinical trial is subject to clinical and FDA approval risks.
---

Financials

Annual

Ownership Overview

54.51%1.38%8.39%35.73%
54.51%
Insiders
8.39% Other Institutional Investors
35.73% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

CCEL FAQ

What was Cryo-Cell International Inc’s price range in the past 12 months?
Cryo-Cell International Inc lowest stock price was $3.67 and its highest was $8.15 in the past 12 months.
    What is Cryo-Cell International Inc’s market cap?
    Currently, no data Available
    When is Cryo-Cell International Inc’s upcoming earnings report date?
    Cryo-Cell International Inc’s upcoming earnings report date is Jul 12, 2024 which is in 77 days.
      How were Cryo-Cell International Inc’s earnings last quarter?
      Cryo-Cell International Inc released its earnings results on Apr 15, 2024. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.08.
        Is Cryo-Cell International Inc overvalued?
        According to Wall Street analysts Cryo-Cell International Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cryo-Cell International Inc pay dividends?
          Cryo-Cell International Inc pays a Notavailable dividend of $0.9 which represents an annual dividend yield of N/A. See more information on Cryo-Cell International Inc dividends here
            What is Cryo-Cell International Inc’s EPS estimate?
            Cryo-Cell International Inc’s EPS estimate is $0.05.
              How many shares outstanding does Cryo-Cell International Inc have?
              Cryo-Cell International Inc has 8,104,477 shares outstanding.
                What happened to Cryo-Cell International Inc’s price movement after its last earnings report?
                Cryo-Cell International Inc reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went down -5.367%.
                  Which hedge fund is a major shareholder of Cryo-Cell International Inc?
                  Currently, no hedge funds are holding shares in CCEL
                  ---

                  Cryo-Cell International Stock Smart Score

                  7
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Company Description

                  Cryo-Cell International Inc

                  Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation service and to advance regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage; and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded on September 11, 1989 and is headquartered in Oldsmar, FL.
                  ---

                  CCEL Stock 12 Months Forecast

                  Average Price Target

                  $9.00
                  ▲(15.38% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","4":"$4","6":"$6","8":"$8","10":"$10"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4,6,8,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.43,7.55076923076923,7.671538461538462,7.792307692307692,7.913076923076923,8.033846153846154,8.154615384615385,8.275384615384615,8.396153846153846,8.516923076923076,8.637692307692308,8.758461538461539,8.87923076923077,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.43,7.55076923076923,7.671538461538462,7.792307692307692,7.913076923076923,8.033846153846154,8.154615384615385,8.275384615384615,8.396153846153846,8.516923076923076,8.637692307692308,8.758461538461539,8.87923076923077,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.43,7.55076923076923,7.671538461538462,7.792307692307692,7.913076923076923,8.033846153846154,8.154615384615385,8.275384615384615,8.396153846153846,8.516923076923076,8.637692307692308,8.758461538461539,8.87923076923077,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.02,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.71,"date":1682035200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.89,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.06,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.91,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Advaxis
                  BioCardia
                  Cormedix
                  Vericel

                  Best Analysts Covering CCEL

                  1 Year
                  Allen KleeMaxim Group
                  1 Year Success Rate
                  6/8 ratings generated profit
                  75%
                  1 Year Average Return
                  +33.96%
                  reiterated a buy rating 9 days ago
                  Copying Allen Klee's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +33.96% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis